Author

Tobias Foierl

Institutions: Hexal (Germany), Sandoz Group AG (Switzerland), Sandoz (Japan)

Observed institutions: Hexal (Germany), Sandoz Group AG (Switzerland), Sandoz (Japan)

ORCID: 0009-0000-5669-8215

Observed ORCID: 0009-0000-5669-8215

OpenAlex ID: A5117551196

The potential role of biosimilars in healthcare sustainability in Latin America

2025 · Rony Schaffel, Paul Cornes, et al. · Expert Opinion on Biological Therapy · 5

In-Use Physicochemical Stability of Sandoz Rituximab Biosimilar in 0.9% Sodium Chloride Solution After Prolonged Storage at Room Temperature Conditions

2024 · Roman Borišek, André Mischo, et al. · Drugs in R&D · 3

Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP

2024 · Boris Kubuschok, Burkhard Otremba, et al. · Annals of Hematology · 1

P054 Safety outcomes with GP2015 (etanercept biosimilar) in psoriasis: real-world evidence from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

2025 · Kave Shams, Cristofer Salvati, et al. · British Journal of Dermatology

Works count: 4

Citation count: 9

H-index: 2

I10-index: